HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a $15 price target.
August 04, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $15 indicates the firm's continued confidence in the stock's potential, which could drive investor interest and potentially boost the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100